Login / Signup

Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.

Fatema AlrashedHajer AlasfourMohammad Shehab
Published in: JGH open : an open access journal of gastroenterology and hepatology (2022)
Regarding COVID-19-related hospitalization in IBD, anti-TNFs and ustekinumab were associated with decreased risk of hospitalization. In addition, vedolizumab and tofacitinib were not associated with COVID-19-related hospitalization.
Keyphrases
  • coronavirus disease
  • sars cov
  • ulcerative colitis
  • rheumatoid arthritis
  • respiratory syndrome coronavirus
  • cardiovascular events
  • drug induced